摘要
2022年2月,国际血脂专家组(ILEP)发布《他汀相关肌肉症状患者反安慰药效应的分步诊断与管理意见书》。该意见书对他汀相关肌肉症状进行归因,并提出反安慰药效应(nocebo/drucebo效应)一词,用以形容患者因对他汀药物的不好预期而导致的不良反应,并针对此效应提出以患者为中心的分步诊断与管理措施,以期改善血脂异常人群接受降脂治疗的长期依从性,从而改善预后。该文对这一意见书进行解读。
In February 2022,the International Lipid Expert Panel(ILEP)issued a position paper on step-by-step diagnosis and management of the Nocebo/Drucebo effect in patients with statin-associated muscle symptoms.The document attributes statin-associated muscle symptoms,and put forward the term Nocebo/Drucebo effect to describe the adverse events(AE)caused by patients'poor expectations of statins,for which the patient-centered step-by-step diagnosis and management measures were developed to improve the long-term compliance of lipid-lowering treatment in people with dyslipidemia,to improve the prognosis.This article interprets this position paper.
作者
武刘芸
尹琪楠
韩丽珠
雷洋
边原
郑星月
李炼
童荣生
WU Liuyun;YIN Qinan;HAN Lizhu;LEI Yang;BIAN Yuan;ZHENG Xingyue;LI Lian;TONG Rongsheng(Department of Pharmacy,the Key Laboratory of Personalized Drug Therapy of Sichuan Province,Sichuan Provincial People's Hospital/Affiliated Hospital of University of Electronic Science and Technology of China,Sichuan Academy of Medical Sciences,Chengdu 610072,China)
出处
《医药导报》
CAS
北大核心
2023年第6期777-780,共4页
Herald of Medicine
基金
国家重点研发计划(2020YFC2005500)
四川省科技厅自然科学基金资助项目(2019YFS0514)(2022NSFSC0818)
个体化药物治疗四川省重点实验室开放课题(2021ZD01)
四川省干部保健科研课题(川干研ZH2021-20)。
